Passage Bio, Inc., disclosed in an 8-K filing on January 8, 2025, that it has initiated a restructuring plan aimed at ceasing lab operations at its leased laboratory space in Hopewell, New Jersey, ...

Outlines Strategic Priorities Passage Bio Inc (NASDAQ: PASG) announced initial safety and biomarker data from three Cohort 1 patients in the ongoing global Phase 1/2 upliFT-D clinical trial ...

(RTTNews) - Passage Bio (PASG), a clinical-stage genetic medicines ... of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New ...

10 Stocks to Sell NOW! 3 Stocks to DOUBLE This ... Vestal Point Capital LP boosted its position in Passage Bio by 0.8% in the third quarter. Vestal Point Capital LP now owns 6,100,000 shares ...

Given this risk, we thought we'd take a look at whether Passage Bio (NASDAQ:PASG) shareholders should be worried about its cash burn. In this article, we define cash burn as its annual (negative ...

On Wednesday, December 4th, Orbimed Advisors Llc sold 76,200 shares of Passage Bio stock. The shares were sold at an average price of $0.79, for a total transaction of $60,198.00. 10 Stocks to ...

The buzz around biotech IPOs is continuing through January, with clinical-stage metabolic company Aardvark Therapeutics ...

PHILADELPHIA, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative ...

Passage Bio (PASG – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yun Zhong from ...

Given this risk, we thought we'd take a look at whether Passage Bio (NASDAQ:PASG) shareholders should be worried about its cash burn. In this article, we define cash burn as its annual (negative) free ...